Referencia número: HY-136175

Revumenib

(Synonyms: SNDX-5613)

17 Cited Publications

Revisión del cliente

Based on 17 publication(s) in Google Scholar

Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding K_i of 0.149 nM and a cell based IC₅₀ of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.99%
No. CAS: 2169919-21-3
Fòrmula: C₃₂H₄₇FN₆O₄S
Peso molecular:630.82

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Revumenib Chemical Structure

No. CAS: 2169919-21-3

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- In Vivo
- Ensayo clínico
Chemical Information
Publications (17)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target

Menin-MLL^[1]

Ver todos los productos específicos de isoformas Epigenetic Reader Domain :

In Vivo

Revumenib shows in vivo plasma IC₅₀ of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ensayo clínico

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

No. CAS 2169919-21-3
Appearance Solid
Peso molecular 630.82
Fòrmula C₃₂H₄₇FN₆O₄S
Color White to off-white
SMILES

O=C(N(CC)C(C)C)C1=CC(F)=CC=C1OC2=CN=CN=C2N3CC4(CCN(C[C@H]5CC[C@H](NS(=O)(CC)=O)CC5)CC4)C3
Synonyms

SNDX-5613
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (17)

All Cell Proliferation/Viability AssayRT-PCR2D/3D Cell Culture and DifferentiationIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Cancer Discov

KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs. [Abstract]

2022 Mar 1;12(3):792-811. PMID: 34853079

Revumenib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2022 Mar 1;12(3):792-811. [Abstract]

Relative viability of MOLM-13 cells measured after 6 days treatment of DMSO or M WM-1119, and increasing concentrations of indicated chemicals (SNDX-5613).
Blood

Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor. [Abstract]

2026 Feb 24:blood.2025031486. PMID: 41734382
Blood

Acute myeloid leukemias with UBTF tandem duplications are sensitive to Menin inhibitors. [Abstract]

2024 Feb 15;143(7):619-630. PMID: 37890156

Revumenib purchased from MedChemExpress. Usage Cited in: Blood. 2024 Feb 15;143(7):619-630. [Abstract]

Primary tumors from 5 individual patients (Pt1-5) harboring a UBTF-TD alteration treated with menin inhibitor SNDX-5613 (2.5-2500 nM; 4-14 d) in vitro. Primary sample from a single patient with a RUNX1::RUNX1T1 alteration was used as a control.

Revumenib purchased from MedChemExpress. Usage Cited in: Blood. 2024 Feb 15;143(7):619-630. [Abstract]

MEIS1 mRNA steady-state levels in patient cells treated with SNDX-5613 (2.5-2500 nM).

Revumenib purchased from MedChemExpress. Usage Cited in: Blood. 2024 Feb 15;143(7):619-630. [Abstract]

CFU capacity of UBTF-TD leukemias after exposure to SNDX-5613. Cells from Pt4 and Pt5 were treated with SNDX-5613 (250 nM; 12 d) and then plated in methylcellulose.

Revumenib purchased from MedChemExpress. Usage Cited in: Blood. 2024 Feb 15;143(7):619-630. [Abstract]

Kaplan-Meier curves of UBTF-TD PDX model treated with vehicle or SNDX-5613 ( 75 mg/kg; p.o. twice daily (5 days on, 2 days off) for 5 weeks).
Nat Commun

Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition. [Abstract]

2025 Mar 18;16(1):2641. PMID: 40102405
Leukemia

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. [Abstract]

2023 Jun;37(6):1336-1348. PMID: 36977823
Cell Rep

Menin-MLL1 complex cooperates with NF-Y to promote hepatocellular carcinoma survival. [Abstract]

2025 Dec 23;44(12):116619. PMID: 41296561
Int J Mol Sci

Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia. [Abstract]

2024 May 30;25(11):6020. PMID: 38892207
Microchem J

2025 Apr.
Cancer Sci

Blocking SETD2 Enhances the Therapeutic Efficiency of Menin Inhibitor in MLL-Fusion Leukemia. [Abstract]

2026 May 22. PMID: 42170936
iScience

Recruitment of MLL1 complex is essential for SETBP1 to induce myeloid transformation. [Abstract]

2021 Dec 25;25(1):103679. PMID: 35036869
Anal Bioanal Chem

Dispersive solid-phase extraction as sample pretreatment for determination of chemotherapeutic agents revumenib and venetoclax by HPLC-DAD. [Abstract]

2025 Jul;417(16):3703-3714. PMID: 40323377
bioRxiv

Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell States. [Abstract]

2026 May 26:2026.05.22.726988. PMID: 42244620
Charles University

2026.
bioRxiv

Combinatorial inhibition of LSD1 and Menin induces therapeutic differentiation in AML. [Abstract]

2025 Nov 11:2025.11.09.687496. PMID: 41292878
bioRxiv

Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML. [Abstract]

2025 Oct 15:2025.10.13.681683. PMID: 41279447
bioRxiv

2023 Oct 1.
University of Pennsylvania

2022 Jan 1.

Solvente y solubilidad

In Vitro:

DMSO : ≥ 25 mg/mL (39.63 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.5852 mL

7.9262 mL

15.8524 mL

5 mM

0.3170 mL

1.5852 mL

3.1705 mL

10 mM

0.1585 mL

0.7926 mL

1.5852 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline